|19.76|| +0.13 / +0.66%|
Zogenix, Inc. is a pharmaceutical company, which is engaged in commercializing and developing products for the treatment of central nervous system disorders and pain with novel drug delivery platforms. The company's product portfolio includes: Sumavel DosePro, Zohydro and Relday. The Sumavel DosePro product offers fast-acting, easy-to-use subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The Zohydro product is a 12-hour extended-release formulation of hydrocodone without acetominophen for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. The Relday product is a proprietary, long-acting injectable formulation of risperidone using durect's SABER controlled-release formulation technology in combination with its DosePro needle-free, subcutaneous drug delivery system. Zogenix was founded by Stephen J. Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. Rigby and John J. Turanin on May 11, 2006 and is headquartered in San Diego, CA.
|Stephen J. Farr||President, Chief Executive Officer & Director|
|Ann D. Rhoads||CFO, Secretary, Treasurer & Executive VP|
|Jeff D. Durflinger||VP-Technical Operations & Product Supply|
|Bradley S. Galer||Chief Medical Officer & Executive Vice President|
|Arnold R. Gammaitoni||Vice President-Medical & Scientific Affairs|